PRT1419 as Monotherapy or in Combination With Azacitidine or Venetoclax in R/R Myeloid or B-cell Malignancies

NCT05107856 · clinicaltrials.gov ↗

PHASE1

Phase

TERMINATED

Status

21

Enrollment

INDUSTRY

Sponsor class

Stopped Company Decision

Conditions

Acute Myeloid Leukemia
B-cell Non-Hodgkin Lymphoma
Chronic Lymphocytic Leukemia
Chronic Myelomonocytic Leukemia
Follicular Lymphoma
Mantle Cell Lymphoma
Marginal Zone Lymphoma
Myelodysplastic Syndromes
Myeloproliferative Neoplasm
Small Lymphocytic Lymphoma

Interventions

DRUG: PRT1419
DRUG: Azacitidine
DRUG: Venetoclax

Sponsor

Prelude Therapeutics